drugset / Trial / NCT00765765
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Phase 1/2
Terminated
6 enrolled
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help ixabepilone work better by making tumor cells more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone given together with hydroxychloroquine and to see how well they work in treating patients with metastatic breast cancer.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |